South Korea · Delayed Price · Currency is KRW Remed Statistics
Total Valuation
Remed has a market cap or net worth of KRW 96.28 billion. The enterprise value is 90.66 billion.
| Market Cap | 96.28B |
| Enterprise Value | 90.66B |
Important Dates
The next estimated earnings date is Wednesday, April 1, 2026.
| Earnings Date | Apr 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Remed has 30.91 million shares outstanding. The number of shares has increased by 81.79% in one year.
| Current Share Class | 30.91M |
| Shares Outstanding | 30.91M |
| Shares Change (YoY) | +81.79% |
| Shares Change (QoQ) | +1.46% |
| Owned by Insiders (%) | 35.95% |
| Owned by Institutions (%) | 0.18% |
| Float | 19.80M |
Valuation Ratios
The trailing PE ratio is 182.97.
| PE Ratio | 182.97 |
| Forward PE | n/a |
| PS Ratio | 3.93 |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.50 |
| P/FCF Ratio | 62.95 |
| P/OCF Ratio | 40.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 42.32, with an EV/FCF ratio of 59.28.
| EV / Earnings | 172.30 |
| EV / Sales | 3.70 |
| EV / EBITDA | 42.32 |
| EV / EBIT | 124.91 |
| EV / FCF | 59.28 |
Financial Position
The company has a current ratio of 4.03, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.03 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 2.54 |
| Debt / FCF | 3.55 |
| Interest Coverage | 0.83 |
Financial Efficiency
Return on equity (ROE) is -0.08% and return on invested capital (ROIC) is 2.19%.
| Return on Equity (ROE) | -0.08% |
| Return on Assets (ROA) | 0.80% |
| Return on Invested Capital (ROIC) | 2.19% |
| Return on Capital Employed (ROCE) | 1.54% |
| Weighted Average Cost of Capital (WACC) | 8.52% |
| Revenue Per Employee | 266.36M |
| Profits Per Employee | 5.72M |
| Employee Count | 92 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | -263.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.96% in the last 52 weeks. The beta is 0.73, so Remed's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +1.96% |
| 50-Day Moving Average | 3,061.30 |
| 200-Day Moving Average | 3,283.35 |
| Relative Strength Index (RSI) | 47.46 |
| Average Volume (20 Days) | 230,622 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Remed had revenue of KRW 24.50 billion and earned 526.20 million in profits. Earnings per share was 9.00.
| Revenue | 24.50B |
| Gross Profit | 13.96B |
| Operating Income | 725.84M |
| Pretax Income | -299.35M |
| Net Income | 526.20M |
| EBITDA | 2.14B |
| EBIT | 725.84M |
| Earnings Per Share (EPS) | 9.00 |
Balance Sheet
The company has 13.03 billion in cash and 5.43 billion in debt, with a net cash position of 7.60 billion or 245.78 per share.
| Cash & Cash Equivalents | 13.03B |
| Total Debt | 5.43B |
| Net Cash | 7.60B |
| Net Cash Per Share | 245.78 |
| Equity (Book Value) | 42.05B |
| Book Value Per Share | 1,274.36 |
| Working Capital | 20.89B |
Cash Flow
In the last 12 months, operating cash flow was 2.40 billion and capital expenditures -866.76 million, giving a free cash flow of 1.53 billion.
| Operating Cash Flow | 2.40B |
| Capital Expenditures | -866.76M |
| Depreciation & Amortization | 1.42B |
| Net Borrowing | -2.26B |
| Free Cash Flow | 1.53B |
| FCF Per Share | 49.49 |
Margins
Gross margin is 56.98%, with operating and profit margins of 2.96% and 2.15%.
| Gross Margin | 56.98% |
| Operating Margin | 2.96% |
| Pretax Margin | -1.22% |
| Profit Margin | 2.15% |
| EBITDA Margin | 8.74% |
| EBIT Margin | 2.96% |
| FCF Margin | 6.24% |
Dividends & Yields
Remed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -81.79% |
| Shareholder Yield | -81.79% |
| Earnings Yield | 0.55% |
| FCF Yield | 1.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 8, 2023. It was a forward split with a ratio of 5.
| Last Split Date | Dec 8, 2023 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Remed has an Altman Z-Score of 6.49 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 6 |